Clinical trials: Genital Infection
Bacterial Vaginosis, HUDC_VT
Clinical Study to Evaluate the Efficacy of HUDC_VT in Patients With Bacterial Vaginosis
The objective of the study is to confirm the pharmacological mechanism and evaluate the efficacy and safety after HUDC-VT administration compared to placebo in patients with bacterial vaginosis.
- Conditions
- Bacterial Vaginosis, HUDC_VT, Haudongchun
- Trial name
- NCT03357666
- Testing
- HUDC_VT(Glucose 200mg/Sodium chloride 200mg), HUDC_VT (Glucose 400mg/Sodium chloride 200mg), HUDC_VT (Glucose 400mg)
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Haudongchun Co., Ltd.
Bacterial Vaginosis
A Randomised, Partly-blinded Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Bacterial Vaginosis Compared With an Untreated Control Group
This is a randomised, parallel group, partly blinded investigation to evaluate the clinical performance and safety of pHyph in adult women with bacterial vaginosis.
- Trial name
- Nefertiti 2 (NCT06123299)
- Testing
- pHyph
- Where
- 5 sites in Sweden
- Volunteers
- 61 people
- Sponsor
- Gedea Biotech AB
HIV Infections, HSV-2 Genital Herpes
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013…
- Trial name
- NCT00740584
- Testing
- 3% SPL7013 Gel (VivaGel)
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Randomized, Open-label
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial…
- Conditions
- Randomized, Open-label, Safety, Tolerability
- Trial name
- NCT07663838
- Testing
- GenSci142 capsule, clindamycin phosphate vaginal cream
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
HIV Infections
Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options
This study evaluated the safety and tolerability of tipranavir to improve treatment options for HIV type 1-infected patients who have been previously treated and whose treatment is no longer effective.
- Trial name
- NCT00144287
- Testing
- Tipranavir/Ritonavir
- Where
- 53 sites in Germany
- Volunteers
- 255 people
- Sponsor
- Boehringer Ingelheim
Meningitis, Cryptococcal, HIV Infections
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B
To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in patients who have had an unsatisfactory response to or have experienced unacceptable toxicity with amphotericin B.
- Trial name
- NCT00002306
- Testing
- Fluconazole
- Where
- 14 sites in United States
- Sponsor
- Pfizer
HIV Infections
The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration.
- Trial name
- NCT00002433
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Amgen
HIV Infections
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
To evaluate the single dose pharmacokinetic profile of Viracept pediatric powder formulation administered to HIV infected or exposed children and infants (0 to 13 years of age).
- Trial name
- NCT00002164
- Testing
- Nelfinavir mesylate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Agouron Pharmaceuticals
HIV Infections
Phase I Trial of S-1153 in Patients With HIV Infection
To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible, of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical pharmacokinetic parameters for S-1153.
- Trial name
- NCT00002214
- Testing
- Capravirine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Lexigen Pharmaceuticals
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Protocol V503-021 is a long-term follow-up study of the V503-001 base study (NCT00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of V503 vaccine in preventing cervical cancer and related precancers…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT02653118
- Testing
- V503, GARDASIL
- Volunteers
- 4,453 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
This single arm study will assess the pharmacokinetics, safety and activity of saquinavir (Invirase hard gel capsules, film coated tablets or opened capsules) boosted by combination with ritonavir, in HIV-1 infected infants and…
- Trial name
- NCT00623597
- Testing
- ritonavir, saquinavir [Invirase]
- Where
- 10 sites in Argentina, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
- Trial name
- NCT00002123
- Testing
- Delavirdine mesylate, Didanosine
- Where
- 84 sites in United States, Puerto Rico
- Sponsor
- Pharmacia and Upjohn
HIV Infections
Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects
Racivir ® (RCV) is an experimental drug which means it is not approved for use by the United States Food and Drug Administration (FDA), but it can be used in research studies like this one.
- Trial name
- NCT00121979
- Testing
- Racivir, a non-nucleoside reverse transcriptase inhibitor
- Where
- 6 sites in United States, Argentina and 2 more
- Volunteers
- 60 people
- Sponsor
- Pharmasset
Depression
Antidepressant Treatment of AIDS Related Depression.
To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases.
- Trial name
- NCT00000390
- Testing
- Imipramine hydrochloride
- Where
- United States
- Sponsor
- GEIGY Pharmaceuticals
HIV Infections
TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278
The purpose of this study is to examine the safety, local tolerability and pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of a…
- Trial name
- NCT01031589
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Vulvovaginal Candidiasis
The Study Of Fluconazole For Vulvovaginal Candidiasis
As for the indication of vulvovaginal candidiasis, a single oral administration of fluconazole 150 mg has been approved and is recommended by guidelines overseas.
- Trial name
- NCT01806623
- Testing
- Fluconazole
- Where
- 10 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Pfizer
HIV Infections
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
To compare the efficacy and safety of orally administered didanosine (ddI) with orally administered zidovudine (AZT) in the treatment of patients who exhibit increasing clinical deterioration despite treatment with AZT.
- Trial name
- NCT00002035
- Testing
- Zidovudine, Didanosine
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants
This is a 3 part study of an investigational capsid inhibitor, VH4004280, in healthy adult participants. The purpose is to evaluate the effect of tablet formulation as well as food on bioavailability.
- Trial name
- NCT06168318
- Testing
- VH4004280 Formulation A, VH4004280 Formulation B, VH4004280 Formulation C
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.